English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background    PCA3 (prostate cancer antigen 3 ) gene is one of the most prostate cancer-specific genes at present. Consequently, the prostate-specific expression and the sharp up-regulation of  PCA3  mRNA in prostate cancer suggest a unique transcriptional regulation, which possibly can be attributed to promoter polymorphism. In our study, we evaluated whether there is polymorphism in  PCA3  promoter region and also assess the association of the polymorphism with prostate cancer.    Methodology/Principal Findings  We designed a specific primer set to screen the promoter of  PCA3  gene by polymerase chain reaction (PCR)-based cloning and sequencing with the DNA extracted from peripheral blood samples of prostate cancer (PCa) cases (n = 186) and healthy control cases (n = 135). Genotype-specific risks were estimated as odds ratios (ORs) with associated 95% confidence intervals (CIs) by chi-square test. Possible deviation of the genotype frequencies from controls and PCa cases expected under Hardy-Weinberg equilibrium was assessed by the chi-square test. Short tandem repeat polymorphism of  TAAA  was found in the promoter region of  PCA3  gene, five polymorphisms and eight genotypes were identified. The eight genotypes were divided into three groups: ≤10 TAAA , 11 TAAA , ≥12 TAAA . The group 11 TAAA  and ≥12 TAAA  were associated with higher relative risk for prostate cancer than group ≤10 TAAA  (OR = 1.76, 95%CI = 1.07–2.89[for group 11TAAA]; OR = 5.28, 95%CI = 1.76–15.89[for group ≥12 TAAA ]).    Conclusions/Significance  The presence of the ( TAAA )n short tandem repeat polymorphisms in the  PCA3  promoter region may be a risk factor for prostate cancer in the Chinese population.

Association of Short Tandem Repeat Polymorphism in the Promoter of Prostate Cancer Antigen 3 Gene with the Risk of Prostate Cancer